Skip to main content Skip to office menu Skip to footer
Capital IconMinnesota Legislature

SF 4147

as introduced - 93rd Legislature (2023 - 2024) Posted on 04/16/2024 09:24am

KEY: stricken = removed, old language.
underscored = added, new language.

Current Version - as introduced

Line numbers 1.1 1.2 1.3 1.4 1.5
1.6 1.7 1.8 1.9 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 2.1 2.2 2.3 2.4 2.5 2.6 2.7 2.8 2.9 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17

A bill for an act
relating to health; amending the prescription drug price transparency act; requiring
wholesale drug distributors to provide information by month in the annual report;
amending Minnesota Statutes 2023 Supplement, section 62J.84, subdivision 14.

BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF MINNESOTA:

Section 1.

Minnesota Statutes 2023 Supplement, section 62J.84, subdivision 14, is amended
to read:


Subd. 14.

Wholesale drug distributor prescription drug substantial public interest
reporting.

(a) Beginning January 1, 2024, a wholesale drug distributor must submit to the
commissioner the information described in paragraph (b) for any prescription drug included
in a notification to report issued to the wholesale drug distributor by the department under
subdivision 10.

(b) For each of the drugs described in paragraph (a), the wholesale drug distributor shall
submit to the commissioner no later than 60 days after the date of the notification to report,
in the form and manner prescribed by the commissioner, the following information, if
applicable:

(1) a description of the drug with the following listed separately:

(i) the national drug code;

(ii) the product name;

(iii) the dosage form;

(iv) the strength; and

(v) the package size;

(2) the number of units of the drug product acquired new text begin each month new text end by the wholesale drug
distributor during the 12-month period prior to the date of the notification to report;

(3) the total spent before rebates new text begin each month new text end by the wholesale drug distributor to acquire
the drug product during the 12-month period prior to the date of the notification to report;

(4) the total rebate receivable amount accrued new text begin each month new text end by the wholesale drug
distributor for the drug product during the 12-month period prior to the date of the notification
to report;

(5) the number of units of the drug product sold new text begin each month new text end by the wholesale drug
distributor during the 12-month period prior to the date of the notification to report;

(6) gross revenue from sales in the United States generated new text begin each month new text end by the wholesale
drug distributor for this drug product during the 12-month period prior to the date of the
notification to report; and

(7) total rebate payable amount accrued new text begin each month new text end by the wholesale drug distributor
for the drug product during the 12-month period prior to the date of the notification to report.

(c) The wholesale drug distributor may submit any documentation necessary to support
the information reported under this subdivision.